9-Azido Analogs of Three Sialic Acid Forms for Metabolic Remodeling Of

Total Page:16

File Type:pdf, Size:1020Kb

9-Azido Analogs of Three Sialic Acid Forms for Metabolic Remodeling Of Supporting Information 9-Azido Analogs of Three Sialic Acid Forms for Metabolic Remodeling of Cell-Surface Sialoglycans Bo Cheng,†,‡ Lu Dong,†,§ Yuntao Zhu,†,‡ Rongbing Huang,†,‡ Yuting Sun,†,‖ Qiancheng You,†,‡ Qitao Song,†,§ James C. Paton, ∇ Adrienne W. Paton,∇ and Xing Chen*,†,‡,§,⊥,# †College of Chemistry and Molecular Engineering, ‡Beijing National Laboratory for Molecular Sciences, §Peking−Tsinghua Center for Life Sciences,‖Academy for Advanced Interdisciplinary Studies, ⊥Synthetic and Functional Biomolecules Center, and #Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Peking University, Beijing 100871, China ∇Research Centre for Infectious Diseases, Department of Molecular and Biomedical Science, University of Adelaide, Adelaide SA 5005, Australia Page S1 Table of Contents: Scheme S1.……………………………………………………….........……………. S3 Figure S1……………………………………………………..………..……………. S3 Figure S2……………………………………………………..………..…………… S4 Figure S3……………………………………………………..………..…………… S4 Figure S4……………………………………………………..………..…………… S5 Figure S5……………………………………………………..………..…………… S6 Figure S6……………………………………………………..………..…………….S7 Figure S7……………………………………………………..………..…………….S8 Figure S8……………………………………………………..………..…………….S9 Experimental Procedures……………………………….…........…………....S10-S27 Table S1………………………………………………..………..…………….S28-S48 Supporting Reference……………………………………………….......………...S49 Page S2 Scheme S1. Synthesis of 9AzNeu5Gc Figure S1: a, b, c, d) Representative scatter plots (FSC vs. SSC) and histograms of flow cytometry analysis on Vero cells treated with 9AzNeu5Gc (a, c) or 9AzNeu5Ac (b, d) at varied concentrations. The scatter plots were gated based on the FSC (forward scatter) and SSC (side scatter) signals for cell debris discrimination. The gated cells were used to analyze cell-surface fluorescence. This figure is related to Figure 1b in the main text. Page S3 Figure S2. Evaluation of metabolic incorporation of 9AzNeu5Gc and 9AzNeu5Ac in CHO (a), HeLa (b), and Jurkat cells (c). The cells were treated with 9AzNeu5Gc or 9AzNeu5Ac at varied concentrations for 24 h, reacted with alkyne-PEG4-biotin and stained with streptavidin−Alexa Fluor 488, followed by flow cytometry analysis. MFI (mean fluorescence intensity) was normalized to that of control cells treated with vehicle. Error bars represent mean ± SD from three independent experiments. Figure S3. HeLa cells were treated with 9AzNeuAc or 9AzNeu5Gc at varied concentrations for 24 h. The treated cells were reacted with DBCO-biotin and stained with streptavidin−Alexa Fluor 647. The nuclei were stained with Hoechst 33342 (blue). The cells were imaged by confocal fluorescence microcopy. DIC, differential interference contrast. Scale bar: 50 m. Page S4 Figure S4. HPLC analysis of metabolic incorporation of 9-azido sialic acid analogs. (a) CHO cells were treated with 9AzNeu5Ac, 9AzNeu5Gc, or 9AzKDN for 24 h. (b) Vero cells were treated with 9AzNeu5Ac at varied concentrations for 24 h. (c) MDCK II cells were cultured with 9AzNeu5Ac at varied concentrations for 24 h. The treated cells were lysed, from which the proteins were precipitated and subjected to acid hydrolysis to release ketosidically bound sialic acids. The released sialic acids were then derivatized with DMB and analyzed by HPLC with fluorescence detection. The symbol (*) indicates the peaks of DMB-azido sialic acid. The dashed box indicates no peak of DMB-9AzNeu5Gc in the 9AzNeu5Ac-treated cells. The quantified incorporation ratios were shown on the right. Page S5 Figure S5. Evaluation of metabolic incorporation of 9AzKDN and 9AzNeu5Ac in A375 (a), CHO (b), BJA-B K20 cultured with FBS in the medium (c), Daudi (d), HeLa (e) and Vero cell (f). The cells were treated with 9AzKDN or 9AzNeu5Ac at varied concentrations for 24 h, reacted with alkyne-PEG4-biotin and stained with streptavidin−Alexa Fluor 488, followed by flow cytometry analysis. The zoomed out bar graph inserted highlights 9AzKDN-labeling. MFI (mean fluorescence intensity) was normalized to that of control cells treated with vehicle. Error bars represent mean ± SD from three independent experiments. Page S6 Figure S6: MS analysis of CMP-9AzKDN from CHO cells treated with 9AzKDN. CHO cell was treated with 4 mM 9AzKDN for 24 h. The lysates were separated using HPAEC-UV and the CMP-9AzKDN fraction corresponding to the peak eluting at 29.4 min in figure 2a was collected and analyzed by MALDI-TOF mass spectrometry using the cationic mode. Page S7 Figure S7. HPAEC-UV/PAD analysis of CMP-9AzKDN from BJA-B K20 cells treated with 4 mM 9AzKDN or vehicle for 24 h in medium containing FBS. Pure CMP-9AzKDN was shown as the standard. Pure CMP-9AzKDN was co-injected with the 9AzKDN-treated sample to further validate the CMP-9AzKDN peak. Page S8 Figure S8. Competitive metabolic incorporation of azido sialic acid analogs with Neu5Ac in CHO and PA-1 cells. (a) CHO cells were treated with 4 mM 9-azido sialic acid analog (9AzKDN, 9AzNeu5Gc or 9AzNeu5Ac, respectively) and Neu5Ac at varied concentration for 24 h. (b) PA-1 cells were treated with 4 mM 9-azido sialic acid analog (9AzKDN or 9AzNeu5Ac, respectively) and Neu5Ac at varied concentration for 24 h. The treated cells were reacted with alkyne-PEG4-biotin via BTTAA-assisted CuAAC and stained with streptavidin−Alexa Fluor 488, followed by flow cytometry analysis. MFI (mean fluorescence intensity) was normalized to that of control cells treated with vehicle. Error bars represent mean ± SD from three independent experiments. Page S9 Experimental Procedures General materials. Reagents for chemical synthesis were obtained from commercial sources and used as directly without further purification unless otherwise noted. KDN1, Neu5Gc2, 9AzKDN3, 9AzNeu5Ac4, CMP-Neu5Ac5, CMP- 9AzNeu5Ac6and CMP-9AzKDN5 were synthesized as previously described. Biotin- PEG4-alkyne, DBCO-biotin and Cy5 Alkyne were purchased from Click Chemistry Tools (Scottsdale, AZ, USA), streptavidin-Alexa Fluor 488 and streptavidin-Alexa Fluor 647 were purchased from Invitrogen (Carlsbad, CA, USA), BCA Protein Assay Kit were obtained from Pierce. EDTA-free protease inhibitor cocktail and Nutridoma SP were purchased from Roche. For metabolic incorporation experiments, azido sialic acids were dissolved in PBS (500 mM) and pH was adjusted to 7.4 using NaOH solution, the stock was kept at 4 oC. CMP-9AzKDN was dissolved in PBS (10 mM) and kept at -80 oC. Oregon-Green-labelled SubAB (OG-SubAB) was prepared according to a reported procedure.7 Cell culture. CHO cells (Chinese hamster ovary cell), HeLa cells, MDCK Ⅱ cells, A375 cell and Vero cells were grown in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% FBS (fetal bovine serum), 100 units/mL penicillin and 100 µg/mL streptomycin. PA-1 cells were incubated in MEM supplemented with 10% FBS (fetal bovine serum), 100 units /mL penicillin and 100 µg/mL streptomycin. BJA-B K20 cells (a gift from Prof. Michael Pawlita), Daudi cells and Jurkat cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 units /mL penicillin and 100 µg /mL streptomycin. All the cells were incubated at o 37 C under 5% CO2 in a water-saturated atmosphere. To obtain BJA-B K20 cell in serum-free conditions, the cells were grown carefully for two passages in serum free Page S10 medium (RPMI-1640 with 2 mM L-glutamine containing 1x Nutridoma SP, 50 units/mL penicillin, and 50 μg/mL streptomycin) to deplete endogenous sialic acid. Flow cytometry analysis. After cells were incubated in 6-well plates with azido sialic acids at the indicated concentrations for 24 h. The cells were harvested with trypsin, transferred and distributed into 96-well V-bottomed plate, pelleted (800 g, 6 min, 4 oC), and washed with ice-chilled PBS containing 1% FBS for three times. The pelleted cells were then suspended in PBS containing 0.5% FBS, 50 M alkyne- PEG4-biotin, BTTAA-CuSO4 (50 M CuSO4, BTTAA: CuSO4 = 6:1), and 2.5 mM L- sodium ascorbate at room temperature. After 5 min, the reaction was quenched by adding 1 mM BCS (bathocuproine disulphonate). The cells were washed with cold PBS containing 1% FBS for three times, and incubated with chilled PBS containing 1% FBS and 1 µg/mL Streptavidin-Alexa Fluor 488 for 30 min. After three washes with chilled PBS containing 1% FBS, the cells were suspended in chilled PBS containing 1% FBS and used for FACS (fluorescence-activated cell sorting) analysis on a BD FACSCalibur Flow Cytometer system or BD AccuriTM C6 flow cytometer. In-gel fluorescence scanning. The cells treated with sialic acid probes at the indicated concentrations or vehicle for 24 hours were harvested by trypsin, washed three times with ice-chilled PBS (800 g, 6 min). Then the pelleted cells were lysed in modified RIPA lysis buffer (1% Nonidet P 40, 1% sodium deoxycholate, 0.1% SDS, 50 mM triethanolamine, pH=7.4, 150 mM NaCl, EDTA-free Piercent HaltTM protease inhibitor cocktail, 1 tablet/50 mL). Protein concentrations in the homogenous lysis was normalized to 1 mg/ mL with lysis buffer. The normalized samples were then reacted with 100 µM alkyne-Cy5 in a 60 µL reaction containing premixed BTTAA-CuSO4 complex (50 µM CuSO4, BTTAA: CuSO4 in a 2:1 molar ratio) and 2.5 mM L-sodium ascorbate (freshly prepared). The samples were vortexed for 2 h at 4 °C and resolved on 10% SDS-PAGE gels. The gel was washed in destaining solution (50% methanol, 40% H2O, 10% acetic acid) for 5 min, followed Page S11 by washing in water for another 5 min. After that, the in-gel fluorescence was scanned on a Typhoon FLA 9500 laser scanner (GE Healthcare, USA). Sialylated glycoproteomic identification. For sialylated glycoproteomic identification with three 9-azido sialic acid probes in PA-1 cells, we used a reported procedure.8 Briefly, PA-1 cells treated with azido sialic acid were washed three times in ice-chilled PBS, pelleted and lysed in RIPA buffer. Homogeneous cell lysis was obtained by centrifugation (10,000 × g, 10 min) to remove cell debris. BCA assay was used to determine protein concentration. 5 mg proteins in 5 mL RIPA buffer were incubated with 100 μM alkyne-PEG4-biotin, premixed BTTAA-CuSO4 complex (100 μM CuSO4, BTTAA: CuSO4 at a molar ratio of 2:1), and 2.5 mM L- sodium ascorbate (freshly prepared) for 1 h.
Recommended publications
  • Doctorat De L'université De Toulouse
    HÈSE En vue de l'obtention du DOCTORAT DE L’UNIVERSITÉ DE TOULOUSE Délivré par l'Université Toulouse III - Paul Sabatier Discipline : Biochimie Présentée et soutenue par Violette GAUTIER Le 18 décembre 2012 Développement de méthodes quantitatives sans marquage pour l’étude protéomique des cellules endothéliales JURY Dr. Philippe Marin, IGF/CNRS (Montpellier) – Rapporteur Dr Thierry Rabilloud, iRTSV/LCBM/CNRS (Grenoble) - Rapporteur Dr Sarah Cianferani-Sanglier, IPHC/CNRS (Strasbourg) - Examinatrice Dr. Bernard Monsarrat, IPBS/CNRS (Toulouse) - Directeur de thèse Dr. Anne Gonzalez de Peredo, IPBS/CNRS (Toulouse) – Co-directrice de thèse Pr. Jean-François Arnal, Université Paul Sabatier (Toulouse) - Président Ecole doctorale : Biologie - Santé - Biotechnologies Unité de recherche : Institut de Pharmacologie et de Biologie Structurale (UMR5089, CNRS) Directeurs de Thèse : Bernard Monsarrat, Anne Gonzalez de Peredo Rapporteurs : Philippe Marin, Thierry Rabilloud RESUME La compréhension du fonctionnement des systèmes biologiques, dont les protéines sont les principaux effecteurs, est un défi majeur en biologie. La protéomique est aujourd’hui l’outil incontournable pour l’étude des protéines. Au cours de ma thèse, j’ai donc utilisé différentes approches protéomiques pour répondre à plusieurs questions biologiques autour des cellules endothéliales, concernant l’étude de mécanismes fonctionnels de protéines d’intérêt ainsi que des processus inflammatoires au sein de ces cellules. Ces différentes études ont nécessité la mise en place et l’optimisation de méthodes de quantification sans marquage (« label free ») essentielles à la fois pour la caractérisation de complexes protéiques et pour l’analyse de protéomes entiers. Cette thèse décrit ainsi dans un premier temps l’utilisation de telles approches pour l’analyse de complexes immunopurifiés dans laquelle un enjeu important consiste souvent à discriminer de façon non ambiguë les composants bona fide du complexe par rapport aux contaminants non-spécifiques.
    [Show full text]
  • The Significance of the Evolutionary Relationship of Prion Proteins and ZIP Transporters in Health and Disease
    The Significance of the Evolutionary Relationship of Prion Proteins and ZIP Transporters in Health and Disease by Sepehr Ehsani A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Sepehr Ehsani 2012 The Significance of the Evolutionary Relationship of Prion Proteins and ZIP Transporters in Health and Disease Sepehr Ehsani Doctor of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto 2012 Abstract The cellular prion protein (PrPC) is unique amongst mammalian proteins in that it not only has the capacity to aggregate (in the form of scrapie PrP; PrPSc) and cause neuronal degeneration, but can also act as an independent vector for the transmission of disease from one individual to another of the same or, in some instances, other species. Since the discovery of PrPC nearly thirty years ago, two salient questions have remained largely unanswered, namely, (i) what is the normal function of the cellular protein in the central nervous system, and (ii) what is/are the factor(s) involved in the misfolding of PrPC into PrPSc? To shed light on aspects of these questions, we undertook a discovery-based interactome investigation of PrPC in mouse neuroblastoma cells (Chapter 2), and among the candidate interactors, identified two members of the ZIP family of zinc transporters (ZIP6 and ZIP10) as possessing a PrP-like domain. Detailed analyses revealed that the LIV-1 subfamily of ZIP transporters (to which ZIPs 6 and 10 belong) are in fact the evolutionary ancestors of prions (Chapter 3).
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Figure S1. DMD Module Network. the Network Is Formed by 260 Genes from Disgenet and 1101 Interactions from STRING. Red Nodes Are the Five Seed Candidate Genes
    Figure S1. DMD module network. The network is formed by 260 genes from DisGeNET and 1101 interactions from STRING. Red nodes are the five seed candidate genes. Figure S2. DMD module network is more connected than a random module of the same size. It is shown the distribution of the largest connected component of 10.000 random modules of the same size of the DMD module network. The green line (x=260) represents the DMD largest connected component, obtaining a z-score=8.9. Figure S3. Shared genes between BMD and DMD signature. A) A meta-analysis of three microarray datasets (GSE3307, GSE13608 and GSE109178) was performed for the identification of differentially expressed genes (DEGs) in BMD muscle biopsies as compared to normal muscle biopsies. Briefly, the GSE13608 dataset included 6 samples of skeletal muscle biopsy from healthy people and 5 samples from BMD patients. Biopsies were taken from either biceps brachii, triceps brachii or deltoid. The GSE3307 dataset included 17 samples of skeletal muscle biopsy from healthy people and 10 samples from BMD patients. The GSE109178 dataset included 14 samples of controls and 11 samples from BMD patients. For both GSE3307 and GSE10917 datasets, biopsies were taken at the time of diagnosis and from the vastus lateralis. For the meta-analysis of GSE13608, GSE3307 and GSE109178, a random effects model of effect size measure was used to integrate gene expression patterns from the two datasets. Genes with an adjusted p value (FDR) < 0.05 and an │effect size│>2 were identified as DEGs and selected for further analysis. A significant number of DEGs (p<0.001) were in common with the DMD signature genes (blue nodes), as determined by a hypergeometric test assessing the significance of the overlap between the BMD DEGs and the number of DMD signature genes B) MCODE analysis of the overlapping genes between BMD DEGs and DMD signature genes.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Pro-Inflammatory Tnfα and IL-1Β Differentially Regulate the Inflammatory Phenotype of Brain Microvascular Endothelial Cells Simon J
    O’Carroll et al. Journal of Neuroinflammation (2015) 12:131 JOURNAL OF DOI 10.1186/s12974-015-0346-0 NEUROINFLAMMATION RESEARCH Open Access Pro-inflammatory TNFα and IL-1β differentially regulate the inflammatory phenotype of brain microvascular endothelial cells Simon J. O’Carroll1,2, Dan Ting Kho1,3, Rachael Wiltshire1, Vicky Nelson1,3, Odunayo Rotimi1,2, Rebecca Johnson1,3, Catherine E. Angel4 and E. Scott Graham1,3* Abstract Background: The vasculature of the brain is composed of endothelial cells, pericytes and astrocytic processes. The endothelial cells are the critical interface between the blood and the CNS parenchyma and are a critical component of the blood-brain barrier (BBB). These cells are innately programmed to respond to a myriad of inflammatory cytokines or other danger signals. IL-1β and TNFα are well recognised pro-inflammatory mediators, and here, we provide compelling evidence that they regulate the function and immune response profile of human cerebral microvascular endothelial cells (hCMVECs) differentially. Methods: We used xCELLigence biosensor technology, which revealed global differences in the endothelial response between IL-1β and TNFα. xCELLigence is a label-free impedance-based biosensor, which is ideal for acute or long-term comparison of drug effects on cell behaviour. In addition, flow cytometry and multiplex cytokine arrays were used to show differences in the inflammatory responses from the endothelial cells. Results: Extensive cytokine-secretion profiling and cell-surface immune phenotyping confirmed that the immune response of the hCMVEC to IL-1β was different to that of TNFα. Interestingly, of the 38 cytokines, chemokines and growth factors measured by cytometric bead array, the endothelial cells secreted only 13.
    [Show full text]
  • Loss of the Dermis Zinc Transporter ZIP13 Promotes the Mildness Of
    www.nature.com/scientificreports OPEN Loss of the dermis zinc transporter ZIP13 promotes the mildness of fbrosarcoma by inhibiting autophagy Mi-Gi Lee1,8, Min-Ah Choi2,8, Sehyun Chae3,8, Mi-Ae Kang4, Hantae Jo4, Jin-myoung Baek4, Kyu-Ree In4, Hyein Park4, Hyojin Heo4, Dongmin Jang5, Sofa Brito4, Sung Tae Kim6, Dae-Ok Kim 1,7, Jong-Soo Lee4, Jae-Ryong Kim2* & Bum-Ho Bin 4* Fibrosarcoma is a skin tumor that is frequently observed in humans, dogs, and cats. Despite unsightly appearance, studies on fbrosarcoma have not signifcantly progressed, due to a relatively mild tumor severity and a lower incidence than that of other epithelial tumors. Here, we focused on the role of a recently-found dermis zinc transporter, ZIP13, in fbrosarcoma progression. We generated two transformed cell lines from wild-type and ZIP13-KO mice-derived dermal fbroblasts by stably expressing the Simian Virus (SV) 40-T antigen. The ZIP13−/− cell line exhibited an impairment in autophagy, followed by hypersensitivity to nutrient defciency. The autophagy impairment in the ZIP13−/− cell line was due to the low expression of LC3 gene and protein, and was restored by the DNA demethylating agent, 5-aza-2’-deoxycytidine (5-aza) treatment. Moreover, the DNA methyltransferase activity was signifcantly increased in the ZIP13−/− cell line, indicating the disturbance of epigenetic regulations. Autophagy inhibitors efectively inhibited the growth of fbrosarcoma with relatively minor damages to normal cells in xenograft assay. Our data show that proper control over autophagy and zinc homeostasis could allow for the development of a new therapeutic strategy to treat fbrosarcoma.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Applying Machine Learning to Breast Cancer Gene Expression Data to Predict Survival Likelihood Pegah Tavangar Thesis Submitted T
    Applying Machine Learning to Breast Cancer Gene Expression Data to Predict Survival Likelihood Pegah Tavangar Thesis submitted to the University of Ottawa in partial Fulfillment of the requirements for the Master of Science in Chemistry and Biomolecular Sciences Department of Chemistry and Biomolecular Sciences Faculty of Science University of Ottawa © Pegah Tavangar, Ottawa, Canada, 2020 Abstract Analyzing the expression level of thousands of genes will provide additional information beneficial in improving cancer therapy or synthesizing a new drug. In this project, the expression of 48807 genes from primary human breast tumors cells was analyzed. Humans cannot make sense of such a large volume of gene expression data from each person. Therefore, we used Machine Learning as an automated system that can learn from the data and be able to predict results from the data. This project presents the use of Machine Learning to predict the likelihood of survival in breast cancer patients using gene expression profiling. Machine Learning techniques, such as Logistic Regression, Support Vector Machines, Random Forest, and different Feature Selection techniques were used to find essential genes that lead to breast cancer or help a patient to live longer. This project describes the evaluation of different Machine Learning algorithms to classify breast cancer tumors into two groups of high and low survival. ii Acknowledgments I would like to thank Dr. Jonathan Lee for providing me the opportunity to work with him on an exciting project. I would like to recognize the invaluable counsel that you all provided during my research. It was my honor to work with some other professors in the Faculty of Medicine, such as Dr.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Identification of New Substrates and Physiological Relevance
    Université de Montréal The Multifaceted Proprotein Convertases PC7 and Furin: Identification of New Substrates and Physiological Relevance Par Stéphanie Duval Biologie Moléculaire, Faculté de médecine Thèse présentée en vue de l’obtention du grade de Philosophiae doctor (Ph.D) en Biologie moléculaire, option médecine cellulaire et moléculaire Avril 2020 © Stéphanie Duval, 2020 Résumé Les proprotéines convertases (PCs) sont responsables de la maturation de plusieurs protéines précurseurs et sont impliquées dans divers processus biologiques importants. Durant les 30 dernières années, plusieurs études sur les PCs se sont traduites en succès cliniques, toutefois les fonctions spécifiques de PC7 demeurent obscures. Afin de comprendre PC7 et d’identifier de nouveaux substrats, nous avons généré une analyse protéomique des protéines sécrétées dans les cellules HuH7. Cette analyse nous a permis d’identifier deux protéines transmembranaires de fonctions inconnues: CASC4 et GPP130/GOLIM4. Au cours de cette thèse, nous nous sommes aussi intéressé au rôle de PC7 dans les troubles comportementaux, grâce à un substrat connu, BDNF. Dans le chapitre premier, je présenterai une revue de la littérature portant entre autres sur les PCs. Dans le chapitre II, l’étude de CASC4 nous a permis de démontrer que cette protéine est clivée au site KR66↓NS par PC7 et Furin dans des compartiments cellulaires acides. Comme CASC4 a été rapporté dans des études de cancer du sein, nous avons généré des cellules MDA- MB-231 exprimant CASC4 de type sauvage et avons démontré une diminution significative de la migration et de l’invasion cellulaire. Ce phénotype est causé notamment par une augmentation du nombre de complexes d’adhésion focale et peut être contrecarré par la surexpression d’une protéine CASC4 mutante ayant un site de clivage optimale par PC7/Furin ou encore en exprimant une protéine contenant uniquement le domaine clivé N-terminal.
    [Show full text]